24/7 Market News Snapshot 05 March, 2025 – ZyVersa Therapeutics, Inc. Common Stock (NASDAQ:ZVSA)

March 5, 2025

DENVER, Colo., 05 March, 2025 (247marketnews.com) – (NASDAQ:ZVSA) are discussed in this article.
ZyVersa Therapeutics, Inc. is experiencing significant momentum in the pre-market trading session, with its stock price climbing to $1.198, reflecting a notable increase of 10.93% from the previous close of $1.080. This surge, accompanied by a trading volume of 2.18 million shares, signifies heightened investor interest and confidence in the company’s prospects. As favorable market sentiment surrounds ZyVersa, technical indicators suggest potential resistance levels at $1.25 and support around $1.10, indicating a dynamic market environment where investors should carefully evaluate trends before making decisions.

In a strategic move that may contribute to this optimistic outlook, ZyVersa has announced the publication of promising research on its Inflammasome ASC Inhibitor IC 100, highlighting its potential impact on heart failure with preserved ejection fraction (HFpEF) in individuals with obesity and type 2 diabetes. The peer-reviewed study, featured in Biomedicine & Pharmacotherapy, presents compelling evidence of IC 100’s ability to combat inflammation associated with HFpEF. By targeting the ASC protein across various inflammasome pathways, the inhibitor has demonstrated impressive cardioprotective benefits, including a reduction in pro-inflammatory cytokines, decreased cardiac inflammation, and improved heart function in relevant animal models.

Stephen C. Glover, Co-founder, Chairman, CEO, and President of ZyVersa, emphasized the significance of these findings in highlighting the link between chronic inflammation and cardiovascular disease, reinforcing the company’s focus on addressing obesity and its metabolic complications as a primary indication for IC 100. The enhancement of insulin sensitivity and reduction of blood glucose levels mark a promising avenue for mitigating cardiovascular risks. Looking ahead, ZyVersa plans to initiate two preclinical studies this year, positioning itself to further explore the therapeutic impacts of IC 100 alongside established treatments such as semaglutide. The company’s dedication to developing innovative solutions for inflammatory and renal diseases continues to underscore its commitment to transforming patient care on a global scale.

Related news for (ZVSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.